NCT04603846 - A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

October 1, 2022

Study Completion Date

August 25, 2023

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG

anti-PD-L1 antibody

Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.

DRUG

albumin bound paclitaxel

Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .

Trial Locations (1)

Beijing Tumor Hospital, Beijing